Ultrasound-assisted treatment for acute pulmonary embolism
Official title: Ultrasound-assisted, Catheter-directed Thrombolysis for Acute Intermediate-high-risk Pulmonary Embolism (USAT IH-PE): Impact on Short- and Long-term Outcome, a Multi-center Experience. An Observational Retrospective and Prospective Multi-center Study
Run by Niguarda Hospital · NCT06143969 · Data updated 2026-11-12
This study is testing if using ultrasound to help break up blood clots in patients with serious pulmonary embolism can reduce the chances of developing high blood pressure in the lungs within six months.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 180 (estimated) |
| Sponsor | Niguarda Hospital Academic / other |
| Locations | 1 site (Milan, Italia) |
| Status | Recruiting |
| Started | November 28, 2022 |
| Main results expected | November 30, 2026 |
| Study ends | March 31, 2027 |
| Registry record updated | April 16, 2026 |
| Trial ID | NCT06143969 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults diagnosed with acute intermediate-high-risk pulmonary embolism who meet specific clinical criteria outlined by the European Society of Cardiology.
✕Probably not a fit
Patients under 18 years old, those unable to provide informed consent, or those with certain bleeding disorders may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study evaluates the incidence of pulmonary hypertension within six months following ultrasound-assisted, catheter-directed thrombolysis in patients with acute intermediate-high-risk pulmonary embolism. It includes both retrospective and prospective data collection from multiple centers. The study aims to clarify the effectiveness of this treatment approach, which combines ultrasound technology with targeted thrombolysis to potentially improve outcomes for patients at risk of severe complications from pulmonary embolism.
Why it matters
Potential benefit: If successful, this treatment could reduce the incidence of pulmonary hypertension and improve recovery outcomes for patients with acute pulmonary embolism.
How similar studies have gone: While this approach is innovative, similar studies have shown promise in using catheter-directed therapies for pulmonary embolism, indicating potential for success.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria * Patients admitted with acute intermediate-high risk PE, defined according to ESC guidelines * Symptoms onset within previous 14 days associated or not with deep venous thrombosis * Confirmation of the PE by contrast-enhanced computed tomography of the chest with embolus located in at least one main or proximal lower lobe pulmonary artery * Echocardiographic parameters of RV disfunction * Patients with high-risk PE or hemodynamic deterioration on anticoagulation, who have absolute contraindications (high bleeding risk) to systemic thrombolysis and symptoms onset during the last 14 days. Patients with surgery-related embolic complications are also included (within 48 hours). Exclusion Criteria * Age \< 18 years old * Patients unable to give informed consent * Pregnancy * Patients received fibrinolytic drugs in the preceding 4 days * Bleeding diathesis * Known bleeding disorder * Low platelet count (\< 100.000/uL * Gastrointestinal bleeding in the preceding 3 month * Any ongoing known presence of malignant neoplasia months * Advanced chronic kidney disease (defined as 11.000/uL) * Gastrointestinal bleeding in the preceding 3 month * Any ongoing known presence of malignant neoplasia at admission with survival rate \< 6 * Advanced chronic kidney disease (defined as eGFR \< 30 ml/min or on dialysis)
Where it's running
-
ASST GOM Niguarda
Milan, Italia, Italy Recruiting
Study contacts
- Study coordinator: Alice Sacco, MD
- Email: alice.sacco@ospedaleniguarda.it
- Phone: 0039026444
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
TRiP-cast score test in adults with acute lower-limb injuries requiring immobilization
This study tests whether the TRiP(cast) score can predict risk of blood clots in adults with acute lower-limb injuries treated as outpatients.
-
Prognostic value of the 2026 AHA/ACC PE classification in ED patients with acute PE
This study tests whether the 2026 AHA/ACC five-category PE classification helps predict 30-day major adverse pulmonary embolism events in adults with acute PE presenting to the ED.
-
Right heart dysfunction in acute pulmonary embolism: can echocardiography help predict risk
This study tests whether transthoracic echocardiography can identify right ventricular dysfunction in adults with acute pulmonary embolism to help gauge risk.
-
Aspiration thrombectomy with the Symphony or Prodigy devices
This project will try the Symphony and Prodigy aspiration thrombectomy devices to remove arterial, venous, or pulmonary blood clots in adults.
-
PERC and YEARS approaches for diagnosing pulmonary embolism in the emergency department.
This project will test whether using the PERC score and the YEARS algorithm helps emergency doctors decide which adults need D-dimer blood tests or chest CT scans to diagnose pulmonary embolism.
-
Reperfusion options for acute pulmonary embolism
This project will try catheter-directed interventions or systemic thrombolysis in adults with acute pulmonary embolism to see which approach leads to better outcomes.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.